These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate). Hatano K; Goldberg JB; Pier GB Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies that distinguish inner core, outer core, and lipid A regions of Pseudomonas aeruginosa lipopolysaccharide. de Kievit TR; Lam JS J Bacteriol; 1994 Dec; 176(23):7129-39. PubMed ID: 7525538 [TBL] [Abstract][Full Text] [Related]
4. Polysaccharide antigens of Pseudomonas aeruginosa. Knirel YA Crit Rev Microbiol; 1990; 17(4):273-304. PubMed ID: 1698385 [TBL] [Abstract][Full Text] [Related]
5. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W Front Immunol; 2018; 9():1737. PubMed ID: 30093906 [No Abstract] [Full Text] [Related]
6. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Pier G Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies as probes to examine serotype-specific and cross-reactive epitopes of lipopolysaccharides from serotypes O2, O5, and O16 of Pseudomonas aeruginosa. Lam JS; Handelsman MY; Chivers TR; MacDonald LA J Bacteriol; 1992 Apr; 174(7):2178-84. PubMed ID: 1372599 [TBL] [Abstract][Full Text] [Related]
8. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains. Hatano K; Pier GB Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254 [TBL] [Abstract][Full Text] [Related]
17. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa. Farjaha A; Owlia P; Siadat SD; Mousavi SF; Shafieeardestani M J Biotechnol; 2014 Dec; 192 Pt A():240-7. PubMed ID: 25449544 [TBL] [Abstract][Full Text] [Related]
18. [Experimental study of the protective activity of vaccines made from 7 Pseudomonas aeruginosa immunotypes]. Kholodkova EV; Fedotova IuM; Stanislavskiĭ ES Zh Mikrobiol Epidemiol Immunobiol; 1987 Aug; (8):47-50. PubMed ID: 2446445 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521 [TBL] [Abstract][Full Text] [Related]
20. [Protective artificial polysaccharide-protein antigens made from the O-specific polysaccharides of Pseudomonas aeruginosa bacteria of the immunotypes 1, 2 and 7]. Kul'shin VA; Antsiferova NG; Moroz AF; Dmitriev BA Zh Mikrobiol Epidemiol Immunobiol; 1988 Nov; (11):69-71. PubMed ID: 2464262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]